Additional Study Information: The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian cancer. The Sponsor continues to study rucaparib in several types of cancers, by itself as well as in combination with other drugs. Rucaparib belongs to a class of anti-cancer agents known as PARP inhibitors. PARP is a protein inside cells that helps repair damage to DNA. DNA is the genetic material that carries the instructions for your body's growth and development, and allows cells to continue on living. Cancer can result when there are changes in a persons genetic material (sometimes called DNA mutations) that can cause cancer cells to grow out of control. Research has shown that PARP inhibitors stop the PARP protein from working, and that can sometimes cause cancer cells to stop growing. The goal of this study is to find biomarkers in patients with different types of cancers with specific HRR (Homologous Recombination Repair) gene mutations to help doctors decide if rucaparib is a good treatment option. One of the main goals of biomarker research is to develop a diagnostic test that might help show which patients are most likely to benefit from treatment with rucaparib. As part of this study, we will collect samples of your stored tumor tissue that has already been collected (known as archived tumor tissue) and blood to look for biomarkers. Biomarkers are substances such as genetic material (DNA) and proteins found in blood and tumor tissue that might show if a cancer patient is likely to respond or not respond to a treatment.